Week 9 2021
Tobias Else, MD
Dr. Else’s primary appointment is with the Division of Metabolism, Endocrinology and Diabetes. He received his MD degree from the University of Hamburg, Germany. He pursued his clinical training at the University of Hamburg (Residency: Internal Medicine) and the University of Michigan (Residency: Internal Medicine, Fellowship: Endocrinology). His main research interests are the genetics of endocrine tumors. Dr. Else’s clinical practice focuses on the care for patients with benign and malignant endocrine tumors, particularly pheochromocytoma, adrenocortical tumors and neuroendocrine tumors as well as accompanying hormone excess syndromes (e.g Cushing syndrome, primary aldosteronism). Dr. Else has a particular interest in taking care of patients with hereditary syndromes that predispose to the development of endocrine tumors (e.g. Multiple Endocrine Neoplasia (MEN) type 1, MEN2A & MEN2B, Hereditary Paraganglioma Syndrome). He attends the Multidisciplinary Endocrine Oncology Clinic, where patients with tumors receive diagnostic procedures and treatment. In addition he is part of the Cancer Genetics Clinic, which evaluates patients for hereditary syndromes and also facilitates regular exams and surveillance for patients at risk for endocrine tumors. Dr. Else serves on the Clinical Guidelines Subcommittee and the Guidelines Task Force of the Endocrine Society and is the Program Director of the Endocrine Fellowship at the University of Michigan.
Brian Shuch, MD
Associate Professor of Urology; Director, Kidney Cancer Program
Brian Shuch is a urologic oncologist focused on kidney cancer. He trained at UCLA in urology followed by a fellowship at the NCI where he was a member of the Urologic Oncology branch- the leading research center on hereditary kidney cancer. During that time he helped describe the clinical manifestations of SDH kidney cancer and Cowden’s/PTEN Kidney cancer and defined guidelines for hereditary RCC testing. Since coming to Yale he established the GU Cancer Genetics Clinic where patients have multidisciplinary evaluation and treatment. His laboratory research has focused on understanding HLRCC/SDH Cancer syndromes including how Krebs Cycle mutations influence the homologous recombination pathway.
Veda Giri, MD
Veda N. Giri, MD is an Associate Professor in Medical Oncology, Cancer Biology, and Urology at Sidney Kimmel Cancer Center at Thomas Jefferson University. She is a medical oncologist with specialization in clinical cancer genetics. Dr. Giri is Director of Cancer Risk Assessment and Clinical Cancer Genetics at Thomas Jefferson University, where she leads an integrated and comprehensive effort in inherited cancer risk assessment and conducts studies focused on genetic evaluation of cancer risk. She has focused interest in developing the field of genetic counseling and genetic testing for inherited prostate cancer. Dr. Giri started the first Men’s Genetic Risk Clinic in the US in 2014 focused on genetic evaluation of inherited prostate cancer. Dr. Giri also co-chaired the first and second international consensus conference on developing a comprehensive framework and implementation for genetic evaluation of prostate cancer. Her research has contributed insights into the germline spectrum of men undergoing multigene testing for inherited prostate cancer, as well as insights into the needs of men undergoing genetic counseling.
Dr. Giri received her medical degree from Jefferson Medical College (now Sidney Kimmel Medical College), and proceeded to complete her residency in Internal Medicine and fellowship in Hematology-Oncology at the University of Michigan. She then completed advanced training in molecular cancer genetics at Fox Chase Cancer Center (FCCC). From 2006-2014, she directed prostate cancer risk assessment at FCCC, developing studies focused on evaluating the role of genetic markers in prostate cancer risk assessment. Dr. Giri has served on national committees including the National Comprehensive Cancer Network Prostate Cancer Early Detection Panel and NIH PDQ® Cancer Genetics Editorial Board, contributing expertise in cancer risk assessment and prostate cancer genetics.
Rachelle Manookian, MS, CGC
Cancer Risk Counselor
Rachelle Manookian, M.S., C.G.C., is a board-certified genetic counselor specializing in cancer genetics. She has an M.S. in genetic counseling from the Icahn School of Medicine at Mount Sinai, and a B.S. in biological sciences with a focus in neurobiology from University of California Irvine, as well as minors in Spanish literature and cognitive psychology.
Manookian joined City of Hope’s Division of Clinical Cancer Genomics in April 2019. Prior to City of Hope, she was a general adult genetic counselor at the Greater Los Angeles VA Medical Center, where she served veterans across four VA hospitals in Southern California.
Every summer, Manookian volunteers as a one-on-one counselor at Camp Sunshine during their Fanconi Anemia week. She has previous experience volunteering with victims of domestic violence, and is a California state certified domestic violence advocate. She also has special interests in education and bioethics, and her past research investigated the intersection of disability advocacy groups and prenatal genetic counseling sessions.